Neurogenic bladder in patients with traumatic spinal cord injury: Treatment and follow-up by Yıldız, Necmettin et al.
ORIGINAL ARTICLE
Neurogenic bladder in patients with traumatic spinal cord
injury: treatment and follow-up
Neurogenic Bladder Turkish Research Group, N Yıldız1, Y Akkoç2, B Erhan3, B Gündüz3, B Yılmaz4,
R Alaca4, H Gök5, K Köklü6, M Ersöz6, E Çınar2, H Karapolat2, N Çatalbaş1, AN Bardak3, I Turna3,
Y Demir4, S Güneş5, E Alemdaroğlu6 and H Tunç6
Study design: Multi-center, cross-sectional study.
Objectives: Our aim was to evaluate the treatment methods and follow-up of neurogenic bladder in patients with traumatic spinal
cord injury retrospectively using a questionnaire.
Setting: Turkey.
Methods: Three hundred and thirty-seven patients who had spinal cord injury for at least 2 years were enrolled from six centers in the
neurogenic bladder study group. They were asked to fill-out a questionnaire about treatments they received and techniques they used
for bladder management.
Results: The study included 246 male and 91 female patients with a mean age of 42±14 years. Intermittent catheterization (IC)
was performed in 77.9% of the patients, 3.8% had indwelling catheters, 13.8% had normal spontaneous micturition, 2.6%
performed voiding maneuvers, 1.3% used diapers and 0.6% used condom catheters. No gender difference was found regarding the
techniques used in bladder rehabilitation (P40.05). Overall, 63.2% of patients used anticholinergic drugs; anticholinergic drug use
was similar between genders (P40.05). The most common anticholinergic drug used was oxybutynin (40.3%), followed by trospium
(32.6%), tolterodine (19.3%) darifenacin (3.3%), propiverine (3.3%) and solifenacin (1.1%). The specialties of the physicians who
first prescribed the anticholinergic drug were physiatrists (76.2%), urologists (22.1%) and neurologists (1.7%). Only four patients had
previously received injections of botulinum-toxin-A into the detrusor muscle and three of them stated that their symptoms showed
improvement. Most of the patients (77%) had regular follow-up examinations, including urine cultures, urinary system ultrasound and
urodynamic tests, when necessary; the reasons for not having regular control visits were living distant from hospital (15.3%) and
monetary problems (7.7%). Of the patients, 42.7% did not experience urinary tract infections (UTI), 36.4% had bacteriuria but no
UTI episodes with fever, 15.9% had 1-2 clinical UTI episodes per year and 5% had X3 clinical UTIs. The clinical characteristics of
patients with and without UTI (at least one symptomatic UTI during 1 year) were similar (P40.05). The frequency of symptomatic
UTI was similar in patients using different bladder management techniques (P40.05).
Conclusion: The most frequently used technique for bladder rehabilitation in patients with SCI was IC (77.9%). In all, 63.2% of
patients used anticholinergic drugs, oxybutynin being the most commonly used drug. Also, 77% of patients had regular control visits
for neurogenic bladder; 42.7% did not experience any UTIs.
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INTRODUCTION
More than 10 000 people are diagnosed with spinal cord injury (SCI)
in the United States each year. SCI is associated with a high
socioeconomic burden on patients and their families, and has a high
complication rate.1 One of the most important consequences of SCI is
changes in lower urinary tract function. The primary aims for
treatment of neurogenic lower urinary tract dysfunction and their
priorities are: (1) protection of the upper urinary tract, (2)
improvement of urinary continence, (3) restoration of (parts of)
the lower urinary tract function, and (4) improvement of the patient’s
quality of life.2 Although mortality related to urological complications
has been reduced during the past decades, urinary tract problems
continue to be a prominent cause of morbidity after SCI.2–4 Urinary
tract infection (UTI) is the most common complication in patients
with SCI.5,6 Problems related to UTIs are the most frequent reason for
hospital readmissions, and symptoms such as autonomic dysreflexia
and incontinence can cause serious physical disturbances or social
inconvenience in the lives of those with SCI.7 In order to reduce
morbidity and to prevent urological complications, regular follow-up
visits to a spinal cord rehabilitation clinic are required.
The primary aim of the current study was to evaluate the methods
of bladder management and the follow-up of traumatic SCI patients
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with neurogenic bladder retrospectively using a questionnaire. The
secondary aim was to assess the frequency of self-reported UTI,
anticholinergic drug use and injections of botulinum-toxin-A into the
detrusor muscle for bladder problems.
MATERIALS AND METHODS
A total of 337 patients who had SCI for at least 2 years were enrolled in this
study of Turkish neurogenic bladder research group. The study was carried out
in six rehabilitation clinics in four different cities of Turkey between January
and October 2012. The patients were asked to fill out a questionnaire about
treatments they received and techniques they used for bladder rehabilitation.
The patients had help of their physicians during filling the questionnaire.
Approval was obtained from the ethics committee for the study. We certify
that all applicable institutional and governmental regulations concerning the
ethical use of human volunteers were followed during the course of this
research.
Demographic and clinical parameters, including age, gender, marital status,
occupation, employment status, accompanying family members, and the
etiology, level, severity and duration of SCI were recorded. The severity of
SCI was classified into five categories according to the American Spinal Injury
Association Impairment Scale (AIS): A¼ complete lesion, no sensory or motor
function is preserved in the lowest sacral segments; B¼ sensory incomplete
(including segments S4–S5), but no motor function below the neurological
level; C¼ sensory and motor incomplete but more than half of the 10 pairs of
key muscles have a muscle grade o3 on a scale of 0–5; D¼ sensory and motor
incomplete, at least half of the key muscles have a muscle grade X3; and
E¼ sensory and motor function normal.8
The urological questions dealt with methods of bladder management,
regular follow-up visits, UTI and pharmacological treatment (Table 1). Patients
were evaluated in six groups according to the bladder management method
used: (1) normal spontaneous micturition (NSM), (2) micturition with
assisted maneuvers (such as Crede, Valsalva and tapping) (MAM), (3) aseptic
intermittent catheterization (IC), (4) indwelling catheterization (IDC),
(5) condom catheterization (CC), and (6) diaper use. Regular follow-up was
described as control visits according to the physician’s recommendations
(it may be at every 6 months, yearly or biyearly according to the patients’
conditions). The questions about pharmacological treatment in the question-
naire identified the anticholinergic drug used at the time of the questionnaire
was applied.
Clinical and demographic data of the patients were compared according to
the gender of the patients and according to the presence of UTI (at least one
symptomatic UTI during 1 year).
Statistical analysis
The PASW (Predictive Analysis Software) Statistics 19.0 (Statistical Package for
Social Sciences Inc., Chicago, IL, USA) was used for statistical analysis.
Descriptive statistics were used to describe demographic characteristics. For
continuous variables, the significance of the differences was analyzed using the
Student’s t-test, while categorical variables were analyzed using a chi-square
test. The level of significance was set at Po0.05.
RESULTS
The number of eligible patients was 337, and 246 (73%) of them were
male and 91 were (27%) female. The majority of the patients were
those who were admitted to outpatient clinics for neuro-urological
control visit. The remaining group consisted of the patients who
were hospitalized for a short period of time for neuro-urological
re-assessment and further rehabilitation requirements. The median
age was 41 (min: 18, max: 68) years, and the median time since the
injury was 48 (min: 24, max: 324) months. Of these patients, two
refused to have AIS examination due to personal reasons and one of
them could not be evaluated for AIS. Owing to this reason, data
concerning severity and level of the lesion were available for 334
subjects. In total, 161 (48%) had a complete lesion and 173 (52%) an
incomplete lesion. A total of 57 (17%) subjects had tetraplegia and
277 (83%) paraplegia. The main demographic and clinical data of the
patients with SCI are shown in Tables 2 and 3, respectively.
IC was performed in 77.9% of the patients, 13.8% had NSM, 3.8%
had IDC, 2.6% performed MAM, 1.3% used diapers and 0.6%
used CC (Table 3). All the patients in the IDC group were using
urethral catheters. There was no patients with suprapubic catheter.
The numbers of female and male subjects in the bladder management
groups are shown in Table 4.
Table 1 Questions regarding urological problems
1. Method of bladder management
How do you empty your bladder?
( ) Normal spontaneous micturition (NSM)
( ) Micturition with assisted maneuvers (such as Crede, Valsalva and tapping)
(MAM)
( ) Aseptic intermittent catheterization (IC)
( ) Indwelling catheterization (IDC)
( ) Condom catheterization (CC)
( ) Other method, specify (Diapers)
2. Regularly control
Did you have regular follow-up visits to a physician at a rehabilitation clinic for the
neurogenic bladder? (control with urine cultures, urinary system ultrasound and
urodynamic tests, when necessary)
( ) Regular
( ) Not regular (why?)
3. Urinary tract infection (UTI)
Did you have UTI during the last year?
( ) No
( ) Asymptomatic bacteriuria
( ) 1–2 times per year UTI (with symptoms, confirmed by urinary culture and
treated with antibiotics)
( ) X3 times per year UTI (with symptoms, confirmed by urinary culture and
treated with antibiotics)
4. Pharmacological treatment















Did you have any injections of botulinum toxin for neurogenic bladder?
( ) No
( ) Yes
If the answer is yes, did you get any benefit?
( ) No
( ) Yes
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Information about medication was available only in 288 subjects.
Of these, 63.2% (182/288) of the patients used anticholinergic drugs.
The most commonly used anticholinergic drug was oxybutynin
(40.3%), followed by trospium (32.6%), tolterodine (19.3%),
darifenacin (3.3%), propiverine (3.3%) and solifenacin (1.1%). There
was no patients who used a combination of anticholinergics. The
specialties of the physicians who first prescribed the drugs were
physiatrists (76.2%), urologists (22.1%) and neurologists (1.7%).
Only four patients had previously received injections of botulinum-
toxin-A into the detrusor muscle and three of them benefited from
this treatment (Table 3).
Overall, 77% of the patients stated that they had regular follow-up
controls with urine cultures, urinary system ultrasound and urody-
namic tests, when necessary; the reasons for not having regular
controls were living distant from the hospital (15.3%) and monetary
problems (7.7%) (Table 3). In all, 42.7% of the patients had not
experienced UTI, 36.4% had asymptomatic bacteriuria but no UTI
episodes with symptoms, 15.9% had 1–2 clinical UTI episodes per
year and 5% had X3 clinical UTIs (Table 3).
Table 4 shows the comparison of the level and severity of the spinal
cord lesion, ambulation status, bladder rehabilitation techniques,
anticholinergic drug use, UTI and regular control visits in patients
with SCI according to gender. The demographic and clinical data of
the female and male patients were similar (P40.05).
Table 5 shows the comparison of the level and severity of the spinal
cord lesion, gender, ambulation status, methods of bladder manage-
ment, anticholinergic drug use and regular control visits in patients
with SCI according to the presence of symptomatic UTI (at least one
symptomatic UTI during 1 year). Although it was observed that
symptomatic UTI rate was higher among patients with complete
injuries and among patients using IDC and MAM, there was no
Table 2 Demographic features of the spinal cord injured (SCI)
patients
Demographic features
















Employment status, n (%)
Working at present 24 (7.1)
Unemployed/retired 312 (92.9)





Other relatives 6 (1.8)
Caregiver 6 (1.8)
Table 3 Clinical features of spinal cord injured patients
Clinical features
Time elapsed since injury (months), median (min–max) 48 (24–324)
Etiology, n (%)
Motor vehicle accident 116 (34.5)
Fall 101 (30.1)
Gunshot injury 21 (6.3)
Landslip 11 (3.3)
Diving (shallow water) 7 (2.1)
Penetrating/stabbing injury 1 (0.3)
Others 79 (23.5)










Ambulation status, n (%)
Independently 27 (8.6)
Canadian or walker aided 63 (20.1)
Canadian or walker plus AFO or KAFO 74 (23.6)
Wheelchair 149 (47.6)
Bladder management methods, n (%)
Aseptic intermittent catheterization (IC) 243 (77.9)
Normal spontaneous micturition (NSM) 43 (13.8)
Indwelling catheterization (IDC) 12 (3.8)
Micturition with assisted maneuvers (MAM) 8 (2.6)
Diapers 4 (1.3)
Condom catheterization (CC) 2 (0.6)
Anticholinergic drug use for bladder problems n (%)
Yes 182 (63.2)
No 106 (36.8)












Urinary tract infection (UTI), n (%)
No 129 (42.7)
Asymptomatic bacteriuria 110 (36.4)
1–2 times per year UTI 48 (15.9)
X3 times per year UTI 15 (5.0)
Regular control for neurogenic bladder, n (%)
Yes 241 (77.0)
No 72 (23.0)
Intravesical botulinum-toxin-A injection, n (%)
Yes 4 (1.3)
No 296 (98.7)
Abbreviations: AFO, ankle foot orthesis; AIS, American Spinal Injury Association Impairment
Scale, KAFO, knee ankle foot orthesis.
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significant difference between the patients with and without UTI
(P40.05). The frequency of symptomatic UTI was similar in the
bladder management groups (P40.05).
DISCUSSION
Today, the average lifespan of SCI patients is longer due to recent
improvements in medical care. For this reason, treatment and healing
of problems causing morbidity gains much more importance. Among
these problems are the urological complications. Therefore, the
management of neurogenic bladder dysfunction is a crucial compo-
nent of a rehabilitation program for SCI, because it affects the
morbidity of patients.3,4 The objective of this study was to evaluate
the treatment and follow-up of neurogenic bladder in patients with
traumatic SCI retrospectively using a questionnaire.
Normal voluntary voiding is usually impossible after SCI. In the
Stockholm SCI Study, 34% of the subjects were classified in the
normal micturition group, but at least some of them had functional
impairment or used external compression over lower abdomen.9
In another study performed by Dahlberg et al.,10 the subjects who
reported to have control over their voiding were divided into two
groups: those who had no signs of neurogenic bladder (normal
voiding group, 11% of the study group), and those who reported
Table 4 Comparison of clinical and demographic data of SCI patients
according to gender
Male Female P-value
Age, (years) mean±s.d. 41.4±15.1 44.5±14.4 0.089
Marital status, n (%)
Married 154 (62.6) 59 (64.8) 0.011
Single 80 (32.5) 20 (22.0)
Widow-widower/divorced 12 (4.9) 12 (13.2)
Time elapsed since injury (months),
mean±s.d.
60.1±54.7 80.3±74.9 0.105
Severity of the injury (AIS grades), n (%)
Complete (AIS-A) 118 (48.4) 43 (47.3) 0.443
Incomplete (AIS-B, -C, -D, -E) 125 (51.6) 48 (52.7)
Neurological level of the injury, n (%)
Cervical 44 (18.1) 13 (14.3) 0.575
Thoracic 143 (58.8) 53 (58.2)
Lumbosacral 56 (23.1) 25 (27.5)
Ambulation status, n (%)
Independently 19 (8.4) 8 (14.3) 0.782
Canadian or walker aided 44 (19.4) 19 (22.1)
Canadian or walker plus AFO or KAFO 57 (25.1) 17 (19.8)
Wheelchair 107 (47.1) 42 (48.8)
Bladder management methods, n (%)
Aseptic intermittent catheterization (IC) 178 (78.8) 65 (75.6) 0.197
Normal spontaneous micturition (NSM) 28 (12.4) 15 (17.4)
Indwelling catheterization (IDC) 10 (4.4) 2 (2.3)
Other—Micturition with assisted maneuvers
(MAM)—Diapers—Condom
catheterization (CC)
10 (4.4) 4 (4.6)
Anticholinergic drug use for bladder problems, n (%)
Yes 134 (65.0) 48 (58.5) 0.301
No 72 (35.0) 34 (41.5)
Urinary tract infection (UTI), n (%)
No 90 (41.3) 39 (46.4) 0.457
Asymptomatic bacteriuria 78 (35.8) 32 (38.1)
1–2 times per year UTI 37 (17.0) 11 (13.1)
X3 times per year UTI 13 (6.0) 2 (2.4)
Regular control for neurogenic bladder, n (%)
Yes 172 (75.8) 69 (80.2) 0.533
No 55 (24.2) 17 (19.8)
Abbreviations: AFO, ankle foot orthesis; AIS, American Spinal Injury Association Impairment
Scale; KAFO, knee ankle foot orthesis; SCI, spinal cord injury.
Table 5 Comparison of clinical and demographic data of SCI patients






Age, (years) mean±s.d. 43.4±15.2 40.25±13.9 0.07
Gender, n (%)
Male 168 (70.3) 50 (79.4) 0.08
Female 71 (29.7) 13 (20.6)
Time elapsed since injury
(months), mean±s.d.
73.6±64.8 65.6±46.4 0.92
Severity of the injury (AIS grades), n (%)
Complete (AIS-A) 102 (42.7) 34 (54.0) 0.17
Incomplete (AIS-B, -C, -D, -E) 136 (57.3) 29 (46.0)
Neurological level of the injury, n (%)
Cervical 42 (17.6) 11 (17.5) 0.85
Thoracic 138 (58.0) 35 (55.5)
Lumbosacral 58 (24.4) 17 (27.0)
Ambulation status, n (%)
Independently 22 (9.2) 5 (7.9) 0.76
Canadian or walker aided 50 (20.9) 11 (17.5)
Canadian or walker plus AFO or KAFO 46 (19.2) 21 (33.3)
Wheelchair 121 (50.6) 26 (41.3)
Bladder management methods, n (%)
Aseptic intermittent catheterization
(IC)
181 (76.1) 51 (81.0) 0.13
Normal spontaneous micturition (NSM) 40 (16.8) 3 (4.8)
Indwelling catheterization (IDC) 7 (2.9) 5 (7.9)
Micturition with assisted
maneuvers (MAM)




Anticholinergic drug use for bladder problems, n (%)
Yes 141 (62.4) 41 (66.1) 0.48
No 85 (37.6) 21 (33.9)
Regular control for neurogenic bladder, n (%)
Yes 186 (77.8) 44 (69.8) 0.21
No 53 (22.2) 19 (30.2)
Abbreviations: AFO, ankle foot orthesis, AIS, American Spinal Injury Association Impairment
Scale; KAFO, knee ankle foot orthesis; SCI, spinal cord injury; UTI, urinary tract infection.
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incontinence or those with assisted voiding (controlled voiding group,
12% of the study group). Of the patients in our study, 13.8% of them
had normal micturition.
Clean intermittent catheterization (CIC) has helped to improve our
knowledge of the bladder and reduce the incidence of urinary
complications in patients with SCI.2 Many studies have reported
bladder management methods with the use of CIC ranging from 16%
to 96%.11,12 CIC is considered the ideal management or gold standard
for neurogenic bladder if the patient is willing, physically and
mentally able to perform the task or has caregivers who are able to
assist.13,14 It is usually the primary recommendation for long-term
bladder management.15 In accordance with these studies, our results
revealed that the most frequently used technique for bladder
rehabilitation in patients with SCI is CIC (77.9%).
For practical reasons, reflex voiding and crede or valsalva
maneuvers are still commonly in use, often combined with condom
drainage in men. In addition, IDC (urethral or suprapubic) remain in
common use. Published guidelines are based on reviews of current
literature showing that there are significantly more serious complica-
tions associated with IDC compared with CIC.2 CIC avoids the need
for a permanent foreign body within the bladder and is preferred
over an IDC when addressing hygiene, sexuality, body image and
preservation/improvement in renal function. However, little is known
about what the actual bladder management for the majority of spinal
cord injured patients is in everyday practice. It was noted that CIC
does not find acceptance initially with the patients and their
caregivers. In a recent large study, 24.762 patients with SCI were
followed between 1972 and 2005; the use of CIC increased from
12.6% to 49.6%. On the other hand, IDC use decreased from 33.1%
in 1972 to 23.1% in 2005. The biggest change was in the use of
condom catheterization, which decreased from 34.6% in 1972 to 1.5%
in 2005.3 In our study, CC and IDC usage among SCI patients were
quite low (0.6% and 3.8% respectively) at a mean of 66 months and a
minimum of 24 months follow-up. Our follow-up period was short,
66 months as compared with theirs of 30 years. In the large-scale
study mentioned above, it was also reported that female patients had
a higher risk for using IDC at discharge from rehabilitation and
follow-up.3 Similarly, another study indicated that IDC usage rate was
higher in female patients with impaired hand functions.16 Unlike
these studies, we demonstrated that bladder management was not
different in male and female patients. Lower rate of IDC usage
and relatively small number of participants according to the other
related studies and short follow-up could be the reasons for this
finding.
Absence of other bladder management methods such as sacral
neuromodulation, sacral anterior root stimulation, bladder augmen-
tation and conduit in our study group could be due to relatively small
number of patients and short-term follow-up.
Satisfactory outcomes, however, have been also reported with
conservative methods, which can be combined with oral (antic-
holinergic) and intravesical medication (that is, botulinum-toxin-A)
to improve bladder function.13 Anticholinergic drugs are the first-line
choice for treating neurogenic lower urinary tract dysfunction. They
provide an established approach to managing neurogenic detrusor
overactivity. Anticholinergic drugs are used to stabilise the detrusor
muscle, which reduces its overactivity and makes it moderately
refractory to parasympathetic stimulation. This results in improved
bladder compliance and reduced symptoms of overactive bladder,
which in turn helps to prevent renal and bladder damage and
potentially improve long-term outcomes.2 In a meta-analysis,
including 69 trials with 26 229 patients, similar overall adverse
event profiles were found for darifenacin, fesoterodine, transdermal
oxybutynin, propiverine, solifenacin, tolterodine and trospium
chloride, whereas oral oxybutynin dosages of X10 mg day1 have
less favorable adverse event profiles.17 In our study, 63.2% of the
patients used anticholinergic drugs. Of these, the most commonly
used drug was oxybutynin, followed by trospium and tolterodine. In
the study by Khanna et al.,18 oxybutynin alone was used in 52% of the
patients and was combined with tolterodine in 28% of the patients
and in combination with solifenacin in six patients. In the study by
Dahlberg et al.,10 it was reported that only six patients had been on
anticholinergic medication (oxybutynin) and three patients had used
alpha-blockers (tamsulosin) out of the 119 SCI patients who were
followed up at least a year. In the studies of Sekar et al.14 and Nosseir
et al.,19 the rate of patients using anticholinergic medication was 31%
and 58%, respectively. Combined treatment with anticholinergics and
CIC as part of the conservative treatment still remains the mainstay
of urological management of most SCI patients with detrusor
overactivity and detrusor-sphincter dyssinergia. Hansen et al.,12
conducted a study on 236 SCI patients (193 men, 43 women)
between 10 and 45 years (mean 24.1 years), including 126
paraplegic and 110 tetraplegic patients. That study used a follow-up
questionnaire and a retrospective review of the notes; they determined
that 56% of the patients utilized CIC in bladder emptying, and only
19% used medications. Interestingly, about 40% of those taking
medication were on anticholinergics. Intradetrusor injection with
botulinum-toxin-A has a role in treating drug-resistant neurogenic
detrusor overactivity. Its efficacy has been demonstrated by
randomized placebo-controlled trials in patients with SCI.20,21
Because of its short duration of action, it requires repeated invasive
procedures. The optimal number and long-term effects of
botulinum-toxin-A injections providing efficacy is not clearly
known. Intermittent injections of botulinum-toxin-A will tentatively
bridge the gap between oral treatment and invasive surgical treatment.
Most patients maintained benefit for 10–12 months, and 20%
benefitted for 412 months.22 In our study, botulinum-toxin-A was
used in four patients and three of them expressed improvement. We
feel that the low frequency of botulinum-toxin-A injections to
detrusor observed in our study is due to the policies of health
insurance agencies. Botulinum-toxin-A injections to detrusor are not
paid by health insurance agencies in Turkey.
It is noteworthy that UTI is the most commonly reported
complication of SCI in all series.5,6 No uniform definition of UTI
was used in articles.6,14–16,18,23 In a long-term follow-up (ranged
between 8 and 21 years, with a mean of 17.7 years) study evaluating
the outcomes of bladder management in 119 SCI patients, 61% of the
patients were reported to have complications. UTI stands out as the
most common (80.1%) complication either alone (50%) or in
combination with other complications.16 In the study of Maynard
and Glass,23 the records of SCI patients were retrospectively evaluated
at a mean of 5 years, and symptomatic UTI rate was reported as 30%
in those using CIC as the bladder management method, whereas
Khanna et al.18 determined the rate as 58% at 3 years follow-up.
Biering-Sorensen et al.13 reported that 81% of the patients had been
treated for at least one UTI, 22% had 2–3 UTI per year and 12% of
the patients had X4 UTI per year in 75 patients at 5 years. However,
in our study, 15.9% had 1–2 symptomatic UTI episodes per year and
5% had at least 3 UTIs per year. Weld et al.11 reported that 93% of
their patients developed lower UTI symptoms, whereas the incidence
of UTI in our series was 20.1%. Our results concerning UTI have to
be interpreted with caution as the information was collected
retrospectively. However, they did not define the presentation of
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UTI, and hence it is difficult to accurately compare the incidence of
UTI between these four series.
In our study, in accordance with previous studies, the incidence
of UTI does not seem to be related to gender.14,16 In addition,
demographic and clinical characteristics of the patients, including age,
level and severity of the spinal cord lesion, ambulation status, bladder
management methods, anticholinergic drug use and the regularity of
visits to the rehabilitation clinic, were similar in SCI patients with and
without UTI (at least one symptomatic UTI during 1 year). The
method of urinary drainage is thought to be a very important risk
factor for UTI in SCI population, and IDC with urethral or
suprapubic catheters and urinary diversion are the methods most
likely to lead to persistent bacteriuria. The IDC is a persistent foreign
body and facilitates bacterial growth and migration of uropathogens
upwards through the mucosal sheath surrounding the catheter.
Although the difference was not statistically significant, the
proportion of patients with NSM was higher among patients
without UTI compared with those with UTI. This occasion was
also mentioned in the work by El-Masri et al.16 On the contrary, in
the group with UTI, the proportion of patients with IDC and MAM
was higher than that of patients without UTI, although not at a
statistically significant level. This may suggest that NSM carries less
risk than IDC and MAM. Also in the study by Dahlberg et al.,10 the
subjects in the suprapubic-tapping group had less UTI than those
who used CIC. In our study, the insignificant difference in UTI rates
among patients using different bladder management methods may
be attributed to the small numbers of patients in the bladder
management subgroups, except in the IC group.
There are some limitations of our study that must be considered.
The study population was enrolled from six centers in four different
cities. Although these six centers are the major clinics those serve SCI
population in Turkey, the findings may not reflect the care that is
given in the other clinics throughout Turkey. There may be some
accuracy problem in asymptomatic bacteriuria and UTI frequencies
because of the subjectivity of the reports of the patients. The relatively
small number of the patients in subgroups, lack of data about
long-term follow-up, lack of some detailed data relating to bladder
management and UTIs, retrospective analysis of UTI, using a
questionnaire which was not self-administrated and not validated
and also not including information about the treatment results are
other limitations of our study. The questionnaire should better
include more comprehensive data, but because of the time limitation,
this relatively short and practical questionnaire was used.
CONCLUSIONS
According to the results of this study that were derived from the
data collected retrospectively by the supervised questionnaire, the
most frequently used technique for neurogenic bladder manage-
ment in patients with SCI is IC, and 63% of the patients
with SCI use anticholinergic drugs, oxybutynin being the most
common medication used. In all, 77% of the patients had regular
controls for neurogenic bladder, and 43% did not experience any
UTIs.
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